Researchers from the Korea Advanced Institute of Science and Technology (KAIST) have developed a wearable green organic light-emitting diode (OLED) with a 470-nanometer (nm) wavelength that can cure jaundice in infants.
The OLED provides sufficient power for jaundice treatment even at low voltage, durability for over 100 hours of operation, a low operating temperature of less than 35 Celsius degrees, and flexibility that can endure over 1,000 bends at a 2 mm radius of curvature.
The bilirubin level of the infants’ serum reaches 12 milligrams per decilitre (mg/dL) within three hours of being exposed to the OLED, indicating the completed treatment of jaundice.
Unlike existing light-emitting diode (LED)-based jaundice treatment devices currently used at hospitals, the OLED showed uniform and effective treatment functions.


Gold Price Jumps Near 2% Above $4,080 as Middle East Tensions Lift Safe-Haven Demand
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline
Trump Announces 100% Tariff on Generic Drug Imports Starting in 2028
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options
Wistron Opens $700M Texas AI Factory to Build Nvidia Superchips in U.S.
Oil Prices Extend Four-Day Rally as U.S.-Iran Conflict and Red Sea Threats Raise Supply Fears
Nasdaq Drops as AI Earnings, Oil Surge and Middle East Tensions Weigh on Wall Street
Samsung Eyes Up to $1.14 Billion Investment in AI Startup Mistral
CDC Monitors U.S. Travelers After Hantavirus Outbreak on Luxury Cruise Ship
Gold Price Surges Above $4,100 as Middle East Tensions Boost Safe-Haven Demand
Blue Origin New Glenn Rocket Explodes During Launch Pad Test, Delaying Space Ambitions
Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
Gold Price Climbs Above $4,130 as Middle East Tensions Boost Safe-Haven Demand
European Stocks Slip as Earnings, UK Inflation and ECB Decision Keep Investors on Edge 



